← Back to patent-cliff list
Ketoprofen/Gabapentin
Tier C — Watch / tradeKetoprofen/Gabapentin
Dompé Pharmaceutici Spa
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：COX-2, COX-1, LOXs, CACNA1B, CACNA2D2
Indications (approved)：Back pain
Regional status
US
-
EU
Phase II
2021-10-18
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Ketoprofen/Gabapentin?
Approved indications include: Back pain.
When does the Ketoprofen/Gabapentin patent expire?
No public expiry year is available for Ketoprofen/Gabapentin yet; this page updates once verified.
How do I get a quote for Ketoprofen/Gabapentin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21